Xinda Bio and Sanoki have reached a clinical partnership to develop Xindili monoantigen combination therapy

August 6, Cynda Biopharmaceutical announced that it has reached a clinical research partnership with Beijing Shengnoki Pharmaceutical Technology Co., Ltd. (Shengnoki Pharmaceuticals) to launch an evaluation of SNG1005 and Cynda Bioinnovatable Oncology Drug Dabershu® (recombinant all-human source anti-PD-1 monoclonal antibody, English trademark: Tyvyt®, chemical generic name: Xindili monoanti-injection) joint clinical development of drugs, the proposed development of the adaptive disease for advanced cancer.
SNG1005 is a compound of yew alcohol molecules and amino acids short peptides imported from abroad, the product has completed several Phase II clinical trials in the United States, its Phase III clinical program has been approved by the U.S. Food and Drug Administration (FDA), Sanoki Pharmaceuticals has the right to develop and commercialize in Greater China. The product's Phase II/III clinical trial application for breast cancer brain metastasis in China has been approved by the State Drug Administration (NMPA) and clinical trials are in the process of being initiated. Dabershu'® (Xindili monoantigen injection) is a PD-1 inhibitor developed by Thysta Biopharmaceutical in partnership with Lilly Pharmaceuticals. On December 24, 2018, Dabershu ® (Xindili monoantigen injection) was officially approved by the State Drug Administration for the treatment of relapsed or refractic classic Hodgkin's lymphoma after at least second-line system chemotherapy.
(Agency)